Skip to main navigation
  • Home
  • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
  • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
  • Pipeline
    • Ziftomenib
    • Tipifarnib
    • KO-2806
    • Posters and Presentations
    • Scientific Manuscripts
    • Access To Investigational Drugs Outside a Clinical Study
  • Clinical Trials
    • Overview of Clinical Trials
    • Ziftomenib Clinical Trials
    • KOMET-001 - AML
    • KOMET-007 - AML
    • KOMET-008 - AML
    • Tipifarnib Clinical Trials
    • KURRENT-HN - HNSCC
    • KO-2806 Clinical Trials
    • FIT-001 - Solid Tumors
  • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
      • Calendar Events
      • Corporate Presentations
      • Scientific Publications
    • Corporate Governance
      • Committees and Governance Documents
      • Board of Directors
      • Leadership Team
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact
  • Careers
    • Values
    • Life At Kura
    • Benefits
    • Open Positions
  • Contact
    Top Links
    • News & Media
    • Contact
    Main Menu
    • Home
    • About Us
      • Our Commitment
      • The Story Behind Our Name
      • Leadership
      • Board of Directors
    • Our Approach
      • Precision Medicines
      • Overcoming Resistance
      • Novel Biomarkers
    • Pipeline
      • Ziftomenib
      • Tipifarnib
      • KO-2806
      • Posters and Presentations
      • Scientific Manuscripts
      • Access To Investigational Drugs Outside a Clinical Study
    • Clinical Trials
      • Overview of Clinical Trials
      • Ziftomenib Clinical Trials
      • KOMET-001 - AML
      • KOMET-007 - AML
      • KOMET-008 - AML
      • Tipifarnib Clinical Trials
      • KURRENT-HN - HNSCC
      • KO-2806 Clinical Trials
      • FIT-001 - Solid Tumors
    • Patients & Caregivers
      • Acute Leukemias
      • Head & Neck Cancer
    • Investors
      • Overview
      • Press Releases
      • Events & Presentations
        • Calendar Events
        • Corporate Presentations
        • Scientific Publications
      • Corporate Governance
        • Committees and Governance Documents
        • Board of Directors
        • Leadership Team
      • Financial Information
      • Analyst Coverage
      • FAQs
      • Contact
    • Careers
      • Values
      • Life At Kura
      • Benefits
      • Open Positions
    • Contact
    • MenuMenu

    Corporate Governance

    Submenu
    IR Menu
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Committees & Documents
      • Board of Directors
      • Leadership Team
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact

    Tools

    • Print
    • RSS Feeds
    • Email Alerts

    Committees

    Director Name Audit Committee Compensation Committee Nominating and Corporate Governance Committee
    Helen Collins, M.D. Compensation Committee Nominating and Corporate Governance Committee
    Faheem Hasnain Audit Committee Compensation Committee
    Thomas Malley Audit Committee Nominating and Corporate Governance Committee
    Diane Parks Compensation Committee Nominating and Corporate Governance Committee
    Carol A. Schafer Audit Committee Nominating and Corporate Governance Committee
    Mary Szela Audit Committee Compensation Committee
    Michael Vasconcelles, M.D. Compensation Committee
    = Chairperson = Member = Lead Director = Financial Expert

    Governance Documents

    Audit Committee Charter
    Nominating and Corporate Governance Committee Charter
    Compensation Committee Charter
    Lead Independent Director Charter
    Code of Business Conduct and Ethics

    Tools

    • Print
    • RSS Feeds
    • Email Alerts
    Footer Links - Top
    • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
    • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
    • Pipeline
    • Ziftomenib
    • Tipifarnib
    • KO-2806
    • Posters and Presentations
    • Scientific Manuscripts
    • Access to Investigational Drugs Outside a Clinical Study
    • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
    Footer Links - Clinical Trials
    • Clinical Trials
    • Overview of Clinical Trials
    • Ziftomenib Clinical Trials
    • KOMET-001 – AML
    • KOMET-007 - AML
    • KOMET-008 - AML
    • Tipifarnib Clinical Trials
    • KURRENT-HN – HNSCC
    • KO-2806 Clinical Trials
    • FIT-001 - Solid Tumors
    Footer Links - Investors
    • News & Media
    • Press Releases
    • News & Perspecitives
    • Expert Perspectives
    • Media Resources
    Footer Links - Careers
    • Careers
    • Values
    • Life at Kura
    • Benefits
    • Open Positions
    01 Footer Links - Contact
    • Contact

    Kura Oncology, Inc.
    12730 High Bluff Drive, Suite 400
    San Diego, CA 92130
    (858) 500-8800

    Kura Oncology, Inc.
    2 Seaport Lane, Suite 8A
    Boston, MA 02210
    (617) 588-3755

    Kura Oncology, Inc.
    5510 Morehouse Drive, Suite 110
    San Diego, California 92121

    © 2025 Kura Oncology, Inc. All Rights Reserved | Terms of Use| Privacy Policy

    Scroll to top
    OSZAR »